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INTRODUCTION 
Definition:- 
               Abortion is the expulsion or extraction  of an embryo or fetus   
from its mother weighing 500gms or less  when it is not capable of 
independent survival. (WHO) 
                An abortion can be spontaneous or induced. 
              Spontaneous abortion;- this category includes threatened 
abortion, incomplete, complete, missed abortion. 
             Septic abortion is used to further classify any of these that are 
complicated  further by  infection. 
            Recurrent abortion:-  this term is variably defined and it is meant 
to  identity  women  with  repetitive   spontaneous  abortion  so  that  an  
underlying factor  can be treated to achieve a viable new born 
Induced abortion-surgical or medical termination of a live fetus 
that has not reached the period of  viability. 
About 10-20% of pregnancies end in miscarriage, 10%  are 
induced. Before 16th week most of the miscarriages occur and about 80% 
occur before 12th week of gestation. 
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According to the American college of obstetrics and gynaecology 
(2011); the most effective way to reduce abortions is to prevent unwanted 
and unintended pregnancies. 
Second trimester termination of pregnancy can be done either by 
medical or surgical method.   
Use of the prostaglandin and mifepristone had made second 
trimester termination of pregnancy effective and safe. 
The prostaglandin analogue –misoprostol  was introduced in 1970,  
it  was given by  Vaginal / Oral/ Buccal /sublingual routes. 
           Antiprogestin- mifepristone was introduced in 1980-Shortened the 
induction-abortion interval, dosage of misoprostol required has been 
reduced though the cost is high. 
          The present study is compare the abortifacient efficacy of 
mifepristone with vaginal misoprostol and using misoprostol alone  in the 
mid trimester abortion. 
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MTP ACT 
       Medical  termination   of  pregnancy  (MTP)  was  passed  in  the  Indian  
parliament in 1971 and  it was implented from April 1972. The implented 
rule and regulations were again revised in 1975 for approval of places 
and to make services more available and to eliminate time Consuming 
procedures. 
Indications for termination of pregnancy:- 
MTP can be performed  based on four grounds:- 
1. MEDICAL 
2. EUGENIC 
3. HUMANITARIAN  
4. SOCIAL  
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MEDICAL GROUNDS:- 
Medical grounds when the continuation of pregnancy is likely :- 
-  When the continuation of pregnancy would involve serious risk of 
life or grave injury to the physical and mental health of the patient.  
- The indications are limited and scarcely justifiable now days 
expect in the following cases:- cardiac diseases (Grade  3 an 4)with  
history of decompensation in the previous pregnancy or in between 
the pregnancies. 
-  Chronic glomerulonephritis 
 -  Malignant hypertension  
- Intractable hyperemesis 
- Cervical or breast malignancy 
- Diabetes mellitus with retinopathy 
- Epilepsy or psychiatric illness with advice of the psychiatrist 
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EUGENIC GROUNDS:- 
This is done under the provision of substantial risk of the child 
being  born  with  serious  physical  and  mental  abnormalities  so  as  to  be  
handicapped in life.  
The indication is rare :- 
                 - Structural (Anencephaly) 
                 - chromosomal (Downs syndrome) 
                 - genetic (haemophilia) abnormalities  of the fetus 
                 - When the fetus is  likely to be deformed due to the action of  
teratogenic drugs (warfarin) or radiation exposure(>10rad) in early 
pregnancy. 
                -Rubella viral infection affecting in the first trimester is an 
indication  for termination. 
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HUMANITARIAN GROUNDS 
Humanitarian    grounds   when  pregnancy   is   caused   by   rape 
or  incest. 
SOCIAL GROUNDS:- 
Social grounds when 
- Pregnancy   caused by as a result of contraceptive failure    
VALID LEGAL CONSENT:- 
Pregnancy  can  be  terminated  in  a  minor  girl  (below  the  age  of   
18 yrs)  and lunatics cannot be terminated without  written consent  of  the 
parents or legal guardian (INDIAN LUNATIC ACT 1912) 
Pregnancy can be terminated on the written consent of the woman, 
husband consent is not required. 
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THE PLACE WHERE MTP CAN BE PERFORMED:- 
The act stipulates that no MTP can be performed at any place other   
than. 
1. At  hospital  established   or  maintained  by Government. 
2. A   place  recognized  and approved  by the government,  under 
this act. 
RECOMMENDATIONS:- 
In the revised rules, a registered medical practitioner is qualified to     
perform an MTP:- 
- One has assisted in atleast 25MTP in an authorized center and 
having a certificate 
- 6months house training in obstetrics and gynaecology 
- Diploma or degree holders in obstetrics and gynaecology 
- Pregnancy can be terminated upto 20 weeks. When the pregnancy 
exceeds 12 weeks, opinion of two medical practitioners is required 
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COMPLICATIONS OF MTP:- 
- There is no  universally safe and effective method which is 
applicable in all   cases. However the complications are less 5% 
if termination is done before 8 weeks by MVA or suction 
evacuation. 
- The complications are about five times more in mid- trimester 
abortions. But the use of Prostaglandins has made mid trimester 
abortions  effective and same. 
- The complications are either related to  the methods employed  
or the abortion process.  
MORTALITY:- 
- Below 8wks  of gestation-0.5% 
- 9-12 weeks of gestation -1.6% 
- 11-12 weeks of gestation- 3.3% 
- Risk is found to be increased every 50% at every week of gestation 
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Immediate complications:- 
-  Injury to the cervix (cervical lacerations). 
-  Uterine perforation  during D&E. 
-  Haemorrhage and shock due to trauma, incomplete abortion,
 atonic uterus, or rarely  coagulation failure. 
- Thromobosis or embolism. 
- Postabortal triad of pain, bleeding and low grade fever due 
to  retained clots or products. Antibiotics should be continued, 
 may need repeat evacuation. 
Related to the methods employed; 
Prostaglandins:- intractable vomiting, diarrhoea, fever, uterine 
pain, cervicouterine injury.  
Oxytocin:-  
Water  intoxication, convulsions which occur rarely 
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REMOTE:- 
Gynaecological complications:- 
- menstrual disturbances, 
- chronic pelvic pain,  
- infertility due to cournal block,  
- scar endometriosis (1%),  
- uterine synechiae leading to secondary amenorrhoea 
Obstetrical complications:- 
- recurrent midtrimester abortion due to cervical incompetence, 
- ectopic pregnancy which is increased to threefold, preterm labour, 
- dysmaturity, 
- increased perinatal loss, 
-  rupture uterus during pregnancy and labour,  
- Rh isoimmunisation,  
- Asherman syndrome, 
 -  continuation of pregnancy 
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AIM  OF THE STUDY 
· To compare the abortifacient effect of mifepristone with vaginal 
misoprostol  and misoprostol alone in second trimester  termination 
of pregnancy. 
·  Induction-abortion interval, success rate, outcome were compared.   
· To  compare side-effects and complications. 
· To  compare the cost effectiveness. 
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REVIEW OF LITERATURE 
Termination of pregnancy in second   trimester constitute 10-15% 
of all induced abortions  second  trimester  abortions can  be done by both 
medical and surgical methods.  
The mortality and morbidity in second trimester termination of 
pregnancy is increased to 3-5times than in the first trimester abortions. 
Second trimester abortion management have undergone 
tremendous change with advent of prostaglandin analogues. Medical 
methods are safer comparatively, noninvasive, have no anaesthesia 
complications and have advent over surgical methods. In medical 
abortion, success rate is 95%, morbidity is low and it has been easy 
accessible.   
           Medical abortion is improved with reduction in the risk of 
complication and side effects by using PG analogues  and by using 
mifepristone  prior to prostaglandins. 
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DRUGS USED IN TERMINATION OF SECOND TRIMESTER 
PREGNANCY 
CARBOPROST;- 
Carboprost  tromethamine-250micrograms IM given every 3 hours 
for a maximum 10 doses can be  used. The success rate  is about 90% in 
36  hours.  It  is  contraindicated  in  cases  with  bronchial  asthma.  This  PG  
analogues are not used nowadays. 
SULPROSTONE(PGE2) 
Sulprostone was used for second trimester pregnancy termination 
previously and it  not used now as it causes myocardial infarction and 
coronary vasospam 
 Gemeprost (PGE1) analogue :- 
           Gemeprot can be used in the second trimester termination of 
pregnancy as vaginal pessary .1mg of vaginal pessary every 3-6hoursfor 
five dodes in 24 hours has  got about 90%. The mean induction-abortion 
interval was 14-16 hrs. 
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PROSTAGLADINS:- 
Cervical  ripening   induced  by  prostaglandins by :- 
- directly  acting on the cervix  
- by myometrial activity stimulation 
           A significant role is played by prostaglandin analogues in 
regulation uterine contractility as the receptors present throughout    
pregnancy. 
Prostaglandins Oxygenated metabolites of C20 carboxylic  acid  
and in the most of the biological tissues they are naturally  found .They   
are modulators of cell function and through G- protein receptors   
          The term prostaglandin was coined by VON EULER in 1935 after   
isolating  a substance from accessory glands of male genital tract. 
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CHEMISTRY:- 
Prostaglandins are the biologically active derivatives of 20 carbon 
atom polyunsaturated essential fatty acids that are released from cell 
membrane phospholipids. They are major lipid derived phospholipids. 
Prostaglandins  are considered  to be the derivatives of prostanic acid.  
It has a five membered ring and two side chains projecting in opposite 
directions at right angle to the plane of the ring. 
There are many series of prostaglandins designated as (A, B, C, D, 
E,  F,  G,  H,  I).  Each  series  has  members  with  the  subscript  1,  2,  3  
indicating the number of double bonds in the side chains. 
Prostaglandins  E2, PGF2α and 15—methyl PGF2α are potent 
uterine stimulants, especially in the later part of the pregnancy and cause 
ripening of the cervix. 
Prostaglandins are derived from arachidonic acid present in the 
membrane phosolipids. The cyclooxygenase (COX) Pathway generates 
Prostaglandins with ring structure.  
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        Natural  prostaglandins are unstable compounds that lack specificity 
and are  tolerated poorly , these disadvantages are evaded by the synthetic 
prostaglandins  like misoprostol. 
MISOPROSTOL:-  
Misoprostol  is  a  longer  acting   synthetic  PGE1  analogue  (15-
hydroxy – 16 hydroxy – 16 methyl PGE1 – which has been initially 
developed for prevention and treatment of peptic ulcer . 100mcg and 200 
mcg of misiprostol is manufactured and it can be used as orally, 
vaginally, rectally. 
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Pharmacology:- 
Misoprostol is quickly absorbed and deesterised to its active  
pharmacological form misoprostol acid. When administrated orally,  peak 
level in plasma is attained in  30 minutes and it rapidly  declines  with a 
half life of 20 minutes.  
It is metabolised primarily  in the liver,  and  is excreted in urine. 
Dose of the drug  needs to be  adjusted in liver disease.  In renal disease 
and in dialysis patients , dose needed not to be adjusted. Cytochrome  
P-450 enzyme  system  is not affected by misoprostol. 
Misoprostol binds toEP2/EP3 receptor and thus it is found to be an 
efficient uterotonic agent.   
Misoprostol when administrated vaginally have more advantage in 
reducing gastrointestinal side–effects and on reproductive tract, profound 
effect is exerted and  plasma concentration  peak is reached in one to two 
hours and it declines slowly.  
Oral misoprostol given has less systemic bio availability when 
compared to vaginal misoprostol.  
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Intrauterine pressure is increased by 8 and 25 minutes and 
maximum is reached by 25 and 46 minutes, respectively when 
misoprostol  is administrated  orally or vaginally. Vaginal administration 
of misoprostol causes maximum uterine contractility and long lasting 
action than by oral administration. 
Buccal misoprostol is also found to be effective but it causes tach 
systole . 
 
SIDE-EFFECTS:- 
-  Nausea, vomiting, 
-  headache, malaise, skin rash, fever, 
- diarrhoea. 
- abdominal  cramps. 
- chills. 
- rigor and fever. 
All  these  side  effects are dose dependent. 
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TERATOGENICITY 
Misoprostol causes (Moebius syndrome) in infants 
Malformations :- 
Transverse limb defects  
- Ring shaped constrictions of extremities 
- Arthrogryposis 
- Holoproscencephaly 
- Hydrocephalus 
- Exstrophy of the bladder 
OTHERS USES OF MISOPROSTOL:- 
- Second trimester induction of labour 
- Third trimester for induction of labour 
- In postpartum hemorrhage as a second line drug 
- Cervical ripening prior to curettage 
- NSAID induced gastric ulcers 
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MIFEPRISTONE:- 
Mifepristone commonly known as RU-486 named after Roussel 
Ulcaf company who designed the drug. Mifepristone is a 19 
nortestosterone with weak antiprogestogenic effect with  a bulky-
dimethylamino phenyl substituent at 11 position which induces or 
stabilies  an inactive receptor conformation at 11β position,  hydrophobic 
1 propyl substituent  at 17α position  increases  its  progesterone receptor 
binding affinity.  
Mifepristone has significant antiglucocorticoid and antiandrogenic 
activity. 
Mifepristone  is  a  partial  agonist  and  competitive  antagonist.  At   
both A and B forms of prostaglandins. In the absence of progesterone 
(during anovulatory cycles or after menopause) it exerts weak 
progestational activity- induces predecidual changes , there fore it is now 
regarded as (progesterone receptor modulator). 
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Administration  of  the  drug  (150mg)  during  the  first  3  days  of  the  
follicular phase has no effect on the menstrual cycle. Drug administration 
in the late luteal phase causes luteolysis and prevents pregnancy. 
In medical   abortions, mifepristone act by : 
- blocking the progesterone  receptors  directly  acting  on       
- endometrium causing   decidual   degeneration,   
- causes   cervical  softening  and dilatation,  
- releases endogenous prostaglandins,  
- also increases the sensitivity of myometrium to the 
contractile effects of exogenous prostaglandins and it shortens induction 
– abortion interval and reduction in doses  of prostaglandins required.  
The sensitivity to prostaglandins is about 5 fold increased by 
administrating mifepristone 24-48hrs prior to prostaglandins. In women   
with midtrimester abortions, fetal cord blood concentrations of 
mifepristone ranges from 200ng/ml (30minutes) to 400ng/ml (18hrs)  
following  single oral dose of 100mg. 
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In 12 hrs. the peak maternal concentration is 1500ng/ml and fetal; 
maternal ratio is 0.33.  Mifepristone 200mg is found to be effective than 
600mg when given prior to prostaglandins in inducing medical  
abortions. 
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PHARMOKINECTICS:- 
Mifepristone has a half-life of 26- 30hrs  and it is bioavailability is 
60% It  is largely metabolized  in liver by CYP3A4  .It is excreted in bile 
and faeces. 
By binding  to alpha  acid  glycoprotein  ,mifepristone   is   found 
to be saturated quickly. It interacts with CYP 3A4 inhibitors 
(erythromycin, ketoconazole) and About 85% of the drug is absorbed 
after oral therapy inducers (rifampicin, anticonsvulsants) 
SIDE EFFECTS 
    - Headache (5%) 
    - Gastrointestinsl symptoms of nausea, vomiting (3.5%) 
    - Diarrhoea  
    - Faintness, skin, rash 
    -  Endometrial hyperplasia by reducing progesterone effect 
     - Low potassium and increase in creatinine level 
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Contraindications:- 
- Adrenal failure 
- In presence of IUCD 
- Ectopic pregnancy 
- Hypertension, anaemia, glaucoma, cardiovascular disease, 
smoker, asthmatic      
- Adrenal failure 
- Hemorrhagic disorders 
- Inherited porphyrias 
- Woman on  anticoagulant, glucocortoid therapy 
- Previous uterins scar, scar rupture can occur with 
misoprostol  
- Lactating woman 
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Less common:- 
- cough 
- headache 
- heartburn 
- stuffy or runny nose  
- tightness of chest or wheezing 
- troubled breathing 
OTHER  USES:-    
- uterine fibroids 
- endometriosis 
- glaucoma 
- breast cancer-meningomas 
- prostate cancer 
- ovarian cancer 
- cushing syndrome 
- as emergency contraceptive 
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VARIOUS STUDIES OF MISOPROSTOL 
ROUTES OF ADMINISTRATION:- 
vaginal versus oral 
Bebbington et al conducted   a   randomized  study   where   two  
protocols   of   usage  of   misprostol  – oral  vs vaginal   was  compared in 
second  trimester abortions.  In this study, misoprostol 200microgram 
given vaginally every hour for 3 hours followed by 400micrograms every 
four hours orally or vaginally. In this study, induction to abortion interval 
in the vaginal group is shorter (14.5hrs) when compared to oral group 
(19.6hrs) significantly. In vaginal group-febrile morbidity was higher in 
vaginal group (25%) whereas in oral group(6.7). 
Sublingual versus Vaginal : 
Tang  at  el conducted a study comparing sublingual vs vaginal 
misoprostol 400micrograms given 3 hours upto maximum 5 doses in 
second trimester abortions. In this study, at 24 hours, vaginal misoprostol 
usage resulted in higher success rate 85% when compared to sulingual 
misoprostol which was 64%.At 48 hours, abortion rates were similar in 
both groups. 
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Sublingual versus oral versus vaginal : 
Aronsson at el (2004) studied the effect of misoprostol on uterus 
contractility when given by different routes(sublingual, vaginal, oral).In 
this study, after 24 hrs of administration, the increase in uterine activity in 
these both groups was similar. In this study, there is more rapid effect on 
uterine contractility by sublingual route of administration. 
Interval of administration: 
Jain  et  al conducted a randomized study involving one hundred 
pregnant women between12-22 weeks, 200mg misoprostol  administrated 
intravaginally, 6hrly orv12 hrly for upto 48 hrs. In 6 hrs group – 
incidence of abortion after 48 hrs of initial drug administration was 
87.2% and for 12 hours group it was- 89.2% and mean abortion interval 
for 6 hrs -13.8 hrs and for 12 hrs group – it was 14 hrs. So, conclusion in 
this study, misoprostol was effective for second trimester abortion when 
administrated vaginally and there is no usage in shortening the dosage 
interval from 12 hrs to 6 hrs. 
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Comparison of dosage/dosage administration: 
Herabutya et al showed in a randomized study involving one 
hundred and forty three women 14-26 weeks where 600 mcg  or 800mcg 
of misoprostol is administrated  intravaginally every 12hrs In study, mean 
abortion interval in  12hr group was 15.2hrs while in 800mcg group it 
was15.3hrs and complete abortion rate is 77.6%in 600mcg and in 
800mcg group-72.4%.In this study, 600mcg  given ever 12 hrs was 
considered to be the most effective for mid trimester abortions. 
A study conducted by Ramsey et al concluded that maternal 
cardiac functions is not altered by high dosage vaginal misoprostol-
600microgram by transthoracic electrical bioimpedence monitoring. 
In a study conducted by Ramin KD, Og burn PL, Danielenko,, 
Ramsey PS, high dose oral misoprostol when compared with oxytocin 
infusion is effective in interruption of mid trimester pregnancy. In this 
study, induction to delivery interval in misoprostol -15.2 hrs and with 
oxytocin it was 21.7 hrs. In misoprostol cohort induction abortion – 
interval is shorter 15.2hrs but in oxytocin group it is 21.7hrs. 
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Comparison of misoprostol with other methods: 
Chanduri  et  al conducted a study by comparing vaginal 
misoprostol with ethacridine lactate instilled extra amniotically. Induction 
to abortion interval in misoprostol group-15.5 hrs in ethacridine acetate – 
31.3 hrs. 
In  a  study  conducted  by  Jain  et  al,  misoprostol  200microgram  
administered every 12 hrs is more effective than 20mg PGE2 
administered every 3 hrs for terminating mid trimester pregnancy. 
         Bluementhal et al conducted a study and concluded that 
misoprostol was most effective than PGE2 for second trimester abortions 
by comparing abortion interval, side effects and cost. 
Ho et al conducted a study about the effect of vaginal vs oral 
misoprostol after pre-treatment with mifepristone for mid trimester 
termination of pregnancy. In this study, oral mifepristone 200mg given 
after 36 hrs, vaginal or oral misoprostol 200microgram every three hours 
upto maximum five doses. In vaginal groups, induction abortion interval, 
reduction of dose requirement and success rate were increased. Maximum 
dose used in vaginal group-600mcg  and1000mcg in oral group. 
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In a study conducted by Akory et al, showed the result that vaginal 
misoprostol was found to be effective than those women given oral 
misoprostol and PGF2 instilled intraamniotically by comparing efficacy, 
outcome and acceptability. 
In a study conducted by Gemzell-Danielsson, when mifepristone     
given 36-48hrs  prior to prostaglandins  had shorter abortion interval and 
misoprostol 400mcg administrated vaginally 3hrly to the total 5 vaginal 
doses. In this complete abortion rate was 97% and mean induction –
abortion interval was 6hrs.  
In a prospective randomized double-blind, controlled clinical trial 
conducted by Dickinson et al ,100 women between 14 and 28 weeks 
given 1 mg of gemeprost 3 hourly 5 doses, 200microgram misoprostol 
kept intravaginally 4 doses–6hourly. In this study, intravaginal   
misoprostol is proved as equally effective as gemeprost in second 
trimester termination of pregnancy. 
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In a study conducted by Biswas et al, vaginal administration of 
misoprostol   600microgram followed by 400microgram given 8 hourly 
upto maximum of 48 hrs compared  with 2,150 ml ethacridine 
extraamniotic instillation. 
Mean induction abortion interval in misoprostol administered 
intravaginally was 13.94 hrs when compared to ethacridine acetate – 
28.86 hrs (P< 0.0001) 
In this study they concluded that vaginal misoprostol is found to be 
effective with fewer side effects, cheaper and no complications. 
Previous uterine scar/ previous caesarean:- 
Daskalakis et al conducted  a  study  where  108  patients  were  
subjected  with prior caesarean in midtrimester termination of pregnancy  
uterine  rupture  found  to  be  reported  in   1  case  and  in  patients  with  no  
prior caesarean,  uterine  rupture had been reported in 1  of  216 patients. 
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In a study conducted by Borgatta (2011),where misoprostol  was 
used alone  vaginally or sublingually 400mcg of misoprostol is found to 
be effective than 200 mcg. Doses given every 3 hrs is found to be 
effective than less frequent dosage although intervals upto 12 hrs are 
effective  when high doses of vaginal misoprostol.  (600mcg or 800mcg) 
The evidence based regimen of the Royal College of Obstetrics and 
Gynaecology [RCOG] – (2011)is 800microgram of vaginal misoprostol 
given followed by misoprostol 400microgram every 3 hrs up to 
maximum of 4 doses between 13-22 weeks. 
As per ACOG guidelines (2013)-200mg of mifepristone given  and 
36-48hrs later 400microgram of misoprostol orally every 3hrs upto 5 
doses or 800microgram of vaginal misoprostol given which is followed 
by 400microgram of oral misoprostol every 3 hrs to a maximum of  
4 doses. 
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In a study conducted by Pongsatha et al (2014) among 157 
women  in which  vaginal misoprostol  loading dose regimen 600 mcg 
administrated, then 400 mcg given every 6 hrs compared with a non-
loading dose regimen (400 mcg every 6 hrs). vaginal misoprostol in the 
loading dose regimen was effective than  the non-loading dose regimen. 
VARIOUS STUDIES OF MIFEPRISTONE :- 
Dosage of administration:- 
WebstarD, Templeton A conducted a randomized study by 
administrating mifepristone either 600mg or 200 mg 36 to 48 hrs prior to 
prostaglandins. 
There is no significant difference in geometric mean induction 
abortion interval between two groups 1600microgram is the median dose 
of misoprostol in each group. 
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INTERVAL BETWEEN MIFEPRISTONE AND MISOPROSTOL:- 
D.R.Urquhant and A .A. Templeton conducted a study by giving 
mifepristone 600mg 24, 36 & 48 hrs prior to prostaglandin 
extraamnioticin fusion. In this group-bleeding was not observed in any of 
the groups prior to prostaglandins infusion. 
This study reported that mifepristone can be safely given prior to 
admission to the hospital for termination. 
Mifepristone with misoprostol studies:- 
Suk Wai  Ngai,  Oi  Shan Tang and Pak Chung Ho, conducted a 
randomized study suggesting that oral misoprostol 400microgam is as 
effective as vaginal misoprostol 200microgram given every 3 hrs after 
priming with mifepristone in second trimester pregnancy termination. 
          In a  randomized control study conducted by El Refaey et al, 
600mg of mifepristone given orally and after 36-48 hours and in group  
1- vaginal misoprostol 600mcg given followed by 400 mcg vaginally 
every 3 hrs and  group-2 received 600mcg  of  misoprostol kept vaginally 
and 400mcg of oral misoprostol given every 3hrs upto 4  doses abortion 
rate in this study is 97%. 
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Ashok et al conducted a study by giving mifepristone 200mg orally 
and 36-48 hrs later, 800 microgam of misoprostol  kept  intravaginally 
then 400microgram given orally to a maximum of 4 doses at 3 hr interval. 
In this study, abortion rate is 97%.After the first vaginal dose, induction- 
abortion interval was 6.5hrs.This study shows when first dose of 
misoprostol given vaginally reduces the induction-abortion interval. 
Haitham Hamodal, AllanTempleton, Premila W, Ashok, conducted 
a randomized trial by giving mifepristone 200mg and 36-48 hrs later 
600microgram of misoprostol, given sublingually or 800microgram of 
misoprostol kept intravaginally. Then 400microgram of misoprostol 
given sublingually or vaginally at 3 hourly interval. 
This study suggested that misoprostol when given sublingually 
following mifepristone is effective alternative to vaginal administration 
for 13-20 weeks gestation. 
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Rose  SB,  Shaud  C,  Simmons  A  conducted  a  prospective  study  
among 272 women in second trimester abortion by giving mifepristone  
with vaginal misoprostol. This study supported that when mifepristone 
given prior to misoprostol reduces induction-abortion interval than 
misoprostol used alone. 
In  a  retrospective  analysis  conducted  by  Sin  Ee  Goh,  KOK  Joo  
Thong among 386 women between 12 and 24 weeks gestation. In this 
study, mifepristone 200mg given orally, then 36 to 48 hrs later, 
800microgram of vaginal misoprostol, 400microgram of vaginal 
misoprostol were given every 3hrs to a maximum 4 doses in 24hrs. 
If abortion fails, 200mg mifepristone is given 3hr after the last dose 
of misoprostol then after 12 hrs vaginal misoprostol administrated as 
previous course 97.9% abortion occur within 24 hours and 99.5% within 
36 hours respectively. Nulliparous woman took significantly longer time 
to abort. For incomplete abortion, surgical evacuation of uterus was done 
in about 5%. 
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Kapp N, Stubblefield P, Vragovic O, Moreno N conducted a 
randomized study, placebo controlled, double blind trial of mifepristone 
in termination of second trimester pregnancy using misoprostol after 
feticidal digoxin. 
Dickinson,  J.E.,  Brown  Nell,  P.,  McGinnis   K,  and  NATHAN  
.E.A.  (2010) conducted a study in second trimester termination between 
14-24 weeks of gestation  with   fetal abnormalities diagnosed prenatally 
and misoprostol  alone given in one group  and in other group - 
mifepristone with  misoprostol given the median  induction – abortion 
interval in misoprostol group is 15.5hrs  and  in mifepristone group it is 
8.6hrs which  was comparatively very short.  
Gynuity health projects conducting a study by giving  mifepristone 
+ buccal misoprostol vs buccal misoprostol alone for mid trimester 
abortion (14 – 21 weeks). 
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In a study of Hammond recent advances in second trimester 
abortion, the recommended regimen of Royal College of Obstetrics and 
Gynaecology. (2011) 
DAY ONE: 
Mifepristone 200mg given orally – 36 to 48 hrs later, misoprostol 
800microgram kept intravagnally-then 3 hrs later misoprostol 
400microgram given orally or vaginally every 3 hours until delivery to 
total of 4 doses. If undelivered after 3 hours of 4thdose, repeat 200mg of 
mifepristone +12 hrs later misoprostol may be recommended. 
In a study conducted by Bartley+Baird-200mg of mifepristone 
given, 36-48 hrs later-800microgram of misoprostol vaginally followed 
by orally 400microgram misoprostol-4 doses every 3hrs. Success rate 
was 94% in 24 hrs, Induction  -abortion interval  was 6.1hrs. 
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Ngai et al conducted a study by giving 200mg of mifepristone, and 
36-48 hrs later 400microgram of misoprostol given orally at 3 hrs interval 
to 5 doses. Success rate was 81.4% in 24 hrs. Induction -abortion interval 
was 10.4 hrs. 
NTN  Ngoc  et  al (2011) conducted a randomized controlled trial, 
that pre-treatment with mifepristone – the chance of complete uterine 
evacuation is more than twice -15hrs (79.8% vs 36.9%). In mifepristone 
+ misoprostol group mean induction to abortion interval is shorter 
significantly-10hrs.Complete uterine evacuation in mifepristone-
misoprostol group is 60%-and 20% in misoprostol only group. 
Wildschut  H et  al (2011) did a randomized controlled trial using 
the combination of mifepristone and misoprostol which resulted in 
shortest induction-abortion interval and higher efficacy. 
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Wong MS et al (2012), conducted a comparative study and 
mifepristone plus misoprostol combination had resulted in shortest 
induction-abortion interval.  
As per acog guidelines (2013):- 200mg of mifepristone, 
administered orally, and 24-48hrs  later 800mcg of vaginal misoprostol 
administrated and 400 mcg of  misoprostol administrated vaginally or 
sublingually 3hrly  upto   maximum 5 doses . 600-800mcg of misoprostol 
is administrated vaginally and 3 hrly 400mcg of misoprostol 
administrated vaginally or sublingually  
RCOG Best practice in comprehensive abortion care (2015) -
mifepristone 200mg is administrated orally and 24-48 hrs later, 
misoprostol 800mcg is administrated by vaginal route and every 3hrly 
400mcg given vaginally or sublingually  upto total 5 doses  600-800mcg 
of loading vaginal misoprostol administrated  then every 3 hrly 400mcg 
given by vaginal or sublingual route. 
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MATERIALS AND METHODS 
This study is designed by comparing the efficacy of mifepristone 
with vaginal misoprostol   and with vaginal misoprostol given alone in 
second trimester  abortion at  GOVT .  RSR M LYING IN HOSPITAL  -
CHENNAI- during August 2015-August 2016. 
Study design- Prospective interventional study 
Study Place- Govt. RSRM lying  in hospital Chennai- 
Collaborating Unit-Department of Family Welfare, RSRM 
Study Population: Patients requesting abortion in their second trimester 
at Department of family welfare, RSRM  
Period of study: August 2015- August 2016 
Sample size:100 (patients were randomly subjected) 
GROUP-1-50-Mifepristone+vaginal   misoprostol   
GROUP 2-50- vaginal  misoprostol  alone                                 
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Inclusion Criteria:- 
v 14-20 Weeks of gestation based on menstrual history  and clinical 
examination meet legal criteria to obtain abortion . 
v Women fulfilling MTP  indications as per MTP act. 
v A Single live fetus. 
v Present with closed cervical os, no vaginal bleeding.  
v Patients consenting to this procedure only. 
Exclusion criteria:- 
- history of previous uterine surgery (but not a contraindication). 
- Known allery or contra indications to mifepristone or misoprostol. 
- Presentation in active labour. 
- Lowlying placenta. 
- Multiple fetus. 
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CONTRAINDICATION:- 
- Severe asthma. 
- Known or suspected ectopic pregnancy. 
 - Previous allergy to mifepristone and misoprostol. 
-  Contraindications to mifepristone-Inherited porphyria, Chronic 
adrenal failure, hepatic failure, coagulation disorder. 
- Contraindications to misoprostol usage – glaucoma, mitral 
stenosis, sickle cell anemia, seizures that are poorly controlled. 
Investigations done:- 
- HB% 
- Blood sugar, urea, creatinine, 
- Urine albumin, sugar 
- Blood grouping and Rh typing 
- HIV 
- VDRL 
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 - ECG 
 - Ultrasound 
Inj. Tetanus toxoid 0.5 ml is given before induction of abortion 
Proper consent should be obtained from the patient.   
 
METHODOLOGY:- 
Mifepristone-misoprostol  group:- 
Dosage schedule:- 
DAY 1: Mifepristone 200mg given orally, after 36hrs pt shifted to 
labour ward, 800mcg misoprostol administrated vaginally, 400mcg of 
misoprostol  administrated  every  3  hrs   to  the  total  of  4  doses  if  
undelivered mifepristone can be repeated 3 hrs after the last dose of 
misoprostol and 12 hrs later misoprostol may be given or termination by 
surgical method was considered.  
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Misoprostol group:- 
-  800mcg of misoprostol administrated vaginally 3hrs later 
 misoprostol 400mcg administrated vaginally every 3hrs until 
 abortion occurs or total of 4 doses. 
In case of patients with incomplete abortion, additional 
interventions  adopted –instrumental evacuation, oxytocin infusion. Scan 
was done next day   to   check for  retained  products of conception.  
OUTCOME:- 
Complete: when both fetus or placenta were expelled within 48hrs.  
Incomplete: either fetus or placenta retained.  
Failure: neither fetus nor placenta was expelled. 
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PARAMETERS STUDIED: -    
- Induction-abortion interval, complete abortion rate,  
- success rate, 
-  side-effects 
- Total number of misoprostol doses required 
- Need for additional procedures like curettage, or  
- oxytocin 
Data was analyzed using SPS version 20, Using Anova,  
Chi-Square test Independent sample test and p value of less than 0.05 was 
found to be significant. 
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OBSERVATION  
 
PATIENT CHARCTERISTICS: AGE DISTRIBUTION 
TABLE1: AGE DISTRIBUTION 
 
Age Group 
(Years) 
Mife+Miso 
N=50 
Miso only 
N=50 
TOTAL 
P 
VALUE 
N % N % N % 
0.679 
< 20 8 16% 5 10% 13 13% 
21-25 20 40% 23 46% 43 43% 
26-30 17 34% 19 38% 36 36% 
>30 5 10% 3 6% 8 8% 
TOTAL 50 100% 50 100% 100 100% 
Mean Age In 
Years 
25.54 25.22   
SD 4.546 4.239   
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Most  of  the  patients  are  in  the  age   group  of  21-25yrs  in  either  
groups. 
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TABLE 2: GRAVIDA  
 
Gravida 
Mife+Miso 
N=50 
Miso only 
N=50 
TOTAL 
P 
VALUE 
N % N % N % 
0.682 
1 14 28% 12 24% 26 26% 
2 11 22% 15 30% 26 26% 
3 19 38% 20 40% 39 39% 
4 5 10% 3 6% 8 8% 
5 1 2% 0 0% 1 1% 
TOTAL 50 100% 50 100% 100 100%  
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In mifepristone + misoprostol group, gravida 3 and above -50% in 
misoprostol group it was -48%. 
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TABLE 3: GESTATIONAL AGE GROUP 
GA 
(Weeks) 
Mife+Miso 
N=50 
Miso only 
N=50 
TOTAL 
P 
VALUE 
N % N % N % 
0.492 
14-16 
weeks 
5 10% 2 4% 7 7% 
17-18 
weeks 
29 58% 30 60% 59 59% 
19-20 
weeks 
16 32% 18 36% 34 34% 
TOTAL 50 100% 50 100% 100 100% 
Mean 18.22  18.4    
SD 1.314  1.214    
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In both groups, at 17to 18wks most of the pregnancies were 
terminated.  
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TABLE 4: INDICATIONS FOR TERMINATION 
Indication 
Mife+Miso 
N=50 
Miso only 
N=50 
Total 
P 
Value 
N % N % N % 
0.145 
ANOMALOUS 7 14% 4 8% 11 11% 
UNWANTED 32 64% 32 64% 64 64% 
UNWED 9 18% 11 22% 20 20% 
CONTRACEPTIV
E FAILURE 
2 4% 3 6% 5 5% 
TOTAL 50 100% 50 100% 100 100%  
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In both groups, unwanted pregnancies accounts for sixty four 
percent. 
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TABLE 5: INDUCTION –ABORTION INTERVAL 
Induction 
Abortion 
Mife+Miso 
N=50 
Miso only 
N=50 
P VALUE 
 
 Mean 8.3Hrs 13.9Hrs <0.001** 
SIGNFICANT. Std Deviation 3.598 7.535 
 
MEAN  induction interval in in mifepristone+misoprostol group 
was 8.3hrs which is less when compared with misoprostol group which 
was 13.9hrs , found to be statistically significant. 
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TABLE 6: INDUCTION – ABORTION INTERVAL & PARITY 
Parity Mife+Miso Group  
Hrs 
Miso Group  
Hrs 
G1 12.29 14.24 
G2 8.65 13.53 
G3 6.15 12.46 
G4 & Above 5.15 10.67 
P Value <0.001** 0.876 
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In Primigravida, induction abortion interval prolonged than in 
multigravida in both groups. It is statistically significant in mifepristone 
+  misoprostol group 
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TABLE  7: INDUCTION –ABORTION 
INTERVAL&GESTATIONAL  AGE 
Gestational 
age 
Mife+Miso Group  
Hrs 
Miso Group  
Hrs 
14 -16 Weeks 11.5 12.50 
17-18 Weeks 7.30 12.61 
19-20 Weeks 7.74 14.77 
P Value 0.126 0.676 
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According to gestational age, induction –abortion is not 
statistically significant.  
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TABLE 8: DOSES REQUIRED 
 
Method 
Group 
N Mean 
Std. 
Deviation 
P VALUE 
 
<0.001** Total 
Dosage 
Mife+Miso 50 1368 498.749                     
Miso only 50 2024 382.559 
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Mean dose required in mifepristone+misoprostol group -1368mcg,  
in miso group it was 2024mcg. 
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TABLE  9:  REPEAT DOSE OF MISOPROSTOL REQUIRED 
FOR ABORTION 
Mode 
Number of Doses P-Value 
0 1 2 3 4 
<0.001** Mife+Miso 13 18 8 7 4 
Miso 0 5 9 16 20 
 
The repeat dose required in misoprostol group is comparatively 
more  than in mifepristone+misoprostol group. 
 
 
 
13
18
8
7
4
5
9
16
1
0
2
4
6
8
10
12
14
16
18
20
0 1 2 3 4
N
o.
 o
f P
at
ie
nt
s
No. of  Repeat Dosage for Misoprostol
REPEAT DOSAGE COMPARISON IN 2 MODES
#REF!
#REF!
63 
 
 
 
 
 
ABLE 10:  OUTCOME IN BOTH GROUPS 
 Mife + Miso Group Miso Group P-Value 
 N % N % 
<0.030 
Complete 46 92% 36 72% 
Incomplete 4 8% 13 26% 
Failure 0 0 1 1 
   
 In mifepristone +misoprostol group, 92% aborted completely while 
in misoprostol group it was 72% which was not statistically significant.  
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In mifepristone + misoprostol group, the percentage of incomplete 
is 8% , in misoprostol group -26%  which was not statistically  
significant. 1% of failure in misoprostol group and there is  no failure in 
mifepristone +misoprostol group. 
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TABLE  11: SUCCESS RATES IN BOTH GROUPS 
Hours 
Mife + Miso 
group 
Miso Group P-Value 
0<12 hours 40 80% 16 32% 
<0.001** 
12-24 hours 10 20% 33 66% 
25-36 hours     
37-48 hours     
Failure   1 2% 
 
In mifepristone+misoprostol group -100%aborted successfully 
while misoprostol group -98% aborted successfully within 48 hrs.  
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Patients who expelled within 12 hrs in mifepristone+misoprostol 
group was 80% which was comparatively high when compared with 
misoprostol group which was only 32%. 
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TABLE 12: ADDITIONAL INTERVENTIONS 
Intervetions Mife+Miso Miso 
P VALUE 
 
 
Intrumental 
Evacuation 
4 13 
0.582 
Mife+Miso 
 
0 1 
TOTAL 4 14 
 8% 28% 
 
Additional procedures done  are CU-Tinsertion and tubectomy in 
muitigravida.  
 
 
 
 
 
 
68 
 
 
 
 
 
 
 
About 8% of patients in mifepristone= misoprostol group  needed 
additional interventions which is less when compared to misoprostol 
which was found to be 28% instrumental evacuation  was done in both 
groups. 
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DISCUSSION 
According to the global statistics for abortion rates reported by 
WHO, 1 in 5 pregnancies were aborted  worldwide in 2008 (segh,2012), 
almost half of these abortions were considered unsafe. 
Second trimester termination of pregnancy has tremendous 
improvement  in management by the usage of prostaglandins.  
Mifepristone given  prior   to  prostaglandins  in second  trimester  
abortions resulted in shorter  induction-abortion interval and success rate 
is found to be high though the cost is high. 
This current study  reveals that when mifepristone combined with 
misoprostol resulted in shorter induction–abortion interval and the  
repeated  dosage of the drugs is  reduced  and also their side effects. 
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The study done at GOVT. RSRM LYING IN HOSPITAL is 
prospective interventional study  involving about 100 patients between 
14-20wks. Group1-mifepristone 200mg  is given and after 36hrs-48hrs 
800mcg of vaginal misoprostol given and subsequent doses of 400mcg 
given 3hrly for maximum 4 doses Group2-800mcg of vaginal 
misoprostol followed by 400mcg of vaginal misoprostol 3hrly upto 4 
total doses. 
PATIENT CHARACTERISTICS :- 
AGE :- 
In this study, mean age of patients in mifepristone and misoprostol 
group was 25.54 years and in  misoprostol group  it was 25.22.yrs. The 
age distribution is found to be maximum among 21-25 yrs and above 
30yrs it was less.  
The mean age group in mifepristone and misoprostol was 25.7 
years and in misoprostol group was 25.5yrs  in a study conducted by 
KAPP which was comparable. 
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GRAVIDA :- 
In  this  current  study  patients  with  atleast  one  prior  delivery  
constitute for 22% in mifepristone+ misoprostol group, 30% in 
misoprostol group But in the study conducted by JAN E DICKINSON it 
was 57.8% in mifepristone+ misoprostol group and in misoprostol it was 
60.3%. 
GESTATIONAL AGE :- 
In this study, the mean gestational age in mifepristone=misoprostol 
group was18.22 weeks and in misoprostol group it was 18.40weeks But 
in the study conducted by JAN E DICKINSON mean gestational age 
19.1weeks in mifepristone + misoprostol and in misoprostol group 
19.6weeks. 
INDICATION:-  
In this study, unwanted pregnancy was  found to be the most 
common   indication   for   termination   of   pregnancy  and  it  was  about  
64% in both groups. 
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PARAMETERS STUDIED:- 
Induction- abortion Interval:-    
In this study, in mifepristone + misoprostol group, the mean 
induction – abortion interval was 8.2hrs  and in misoprostol  group, it was 
13.9hrs which was found to be statistically significant. Induction-abortion 
interval is prolonged in primigravida than in multigravida in both  groups. 
In the study conducted by JAN E DICKINSON, mifepristone+ 
misoprostol  and in misoprostol   group   was   found  to be 8.6 hrs and  in  
misoprostol  group  it  was  15.5hrs. 
INDUCTION ABORTION INTERVAL IN PARITY:- 
Induction abortion interval was prolonged with increasing 
gestational age in misoprostol group which was comparable with other 
studies. 
Mean dosage of misoprostol required;- 
In our study, the mean dose of misoprostol in mifepristone + 
misoprostol group was 1368mcg, but in misoprostol group, it was 
2024mcg Repeat dosage of misoprostol required for abortion. 
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In misoprostol group, the repeat doses required was found to be 
comparatively more than in mifepristone – misoprostol group. 
OUTCOME:- 
In mifepristone+ misoprostol, the percentage of complete abortion 
was 92% and in misoprostol group it was 72% In mifepristone+ 
misoprostol group, the rate of incomplete abortion was  only 4% and in 
misoprostol group it was comparatively high 26%. 
Hence when mifepristone given prior to prostaglandins, induction-
abortion interval was found to be shorter and repeated doses of 
misoprostol given was reduced. 
SUCCESS:- 
In Mifepristone + misoprostol, 80% aborted successfully,  but in 
misoprostol  group only 36% aborted within 12hrs.   
In Mifepristone + misoprostol  group 100% aborted successfully at 
24and 48 hrs and in misoprostol  group it was 98 % and was compared 
with other studies. 
 
 
74 
 
 
Additional  Interventions : 
About 4 patients in mifepristone+ misoprostol group required 
additional interventions which was comparatively less compared to 
misoprostol group where 13 patients required additional  interventions. 
 
Most of the patients in misoprostol group required additional 
interventions than in mifepristone +  misoprostol  group.  
 
Side- effects;-  
In mifepristone + misoprostol group, one patient and in 
misoprostol group, three patients  presented  with bleeding  managed by 
surgical evacuation Fever was present in mifepristone- misoprostol group 
was 3%  and in misoprostol group 11% had fever.  
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6%of the patients had nausea when mifepristone given with 
vaginal misoprostol and 15% of the patients had nausea in misoprostol 
group 16% of the patients had when vaginal misoprostol alone given 
which was comparatively less in mifepristone +misoprostol group (6%).   
Other  complications:-   
No major complications were reported with this present study and 
was comparable to other groups. 
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SUMMARY 
In  this  study,  patients  who  are  opting  for  second  trimester  
termination of pregnancy and those with anomalous fetus were subjected.  
In fifty patients, 200mg Mifepristone given after 36hrs, 800mcg  of 
vaginal misoprostol administered and 400mcg of misoprostol   
administrated every 3 hrly  upto 4 maximum doses or till delivery occurs. 
In another fifty patients ,8oomcg  0f vaginal misoprostol given , 
then 400mcg of misoprostol  administrated vaginally every 3 hrs to total 
4 doses or until delivery occurs.  
In both groups, patient age, parity gestational age were compared  
when abortion was induced.  
The maximum age distribution was among 21-25years in both 
groups and the mean age in in mifepristone group was 25.54 and 
misoprostol group it was 25.22. Most of the pregnancies were terminated    
between 17-18 weeks in both groups. 
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In both groups majority of them were multigravida when compared 
with primigravida 
Induction-abortion interval is less in multigravida than in 
primigravida and this was found to be statistically significant of  P value 
of 0.01 in mifepristone+ misoprostol group. 
Unwanted pregnancies which is due to social causes  was the  most 
indication in both groups.    
In mifepristone+misoprostol group, the induction–abortion interval 
was 8.3 hrs which was very less than misoprostol group which was 
13.9hrswhich was found to be statistically significant with  
(p value0.0001) 
By comparing the parameters between  induction- abortion interval 
and gestational age  in both groups was not statistically  found to be 
significant. 
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In mifepristone+ misoprostol group about 100% aborted 
completely while in misoprostol group it was – 98% which is of not 
statistically significant.  
The percentage of incomplete abortion in misoprostol group was 
26%  which was  comparatively  more  when compared to mifepristone + 
misoprostol group  which was only 8%. 
In misoprostol group 1% failure rate was reported and in 
mifepristone+ misoprostol group   there was no failure of abortions which 
was not statistically significant. 
In mifepristone+misoprostol group, within 12 hrs the complete 
abortion rate was 80% which was comparatively high than misoprostol 
group where the complete abortion rate was 32%. 
In mifepristone+ misoprostol group, 100% of patients aborted 
successfully within 48hrs  and in misoprostol group it was 98%. 
  
79 
 
 
Only 8% required additional interventions in mifepristone+ 
misoprostol group, which was comparatively less when compared to 
misoprostol which was about 26%. The procedure adopted commonly 
was instrumental evacuation in both groups. 
The mean dose of misoprostol was 1368mcg in mifepristone+ 
misoprostol group and in misoprostol group alone it was 2024 mcg  
Sideaffects like nausea, pain vomiting,  rigor , fever  were reported more 
in misoprostol  group.  There was no major complications in both groups.  
Mifepristone given prior to prostaglandins  causes no bleeding and 
it can be administrated safely before admission to the hospital. 
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CONCLUSION 
In this study abortifacient efficacy of  combination of mifepristone 
with vaginal misoprostol and with vaginal misoprostol alone in the 
termination of second trimester was compared and following  are the  
conclusion:- 
In Mifepristone + misoprostol combination, the success rate less 
than 12 hrs was 80% but in misoprostol group it was comparatively less -
32% success rare at 24hrs in mifepristone+ misoprostol group was 100% 
The induction-abortion interval was very less Mean induction-
abortion interval in mifepristone+ misoprostol group was 8.3 hrs  which 
was very less when compared to misoprostol group which was 
comparatively high -13.9hrs. 
There was no failure of abortion  in mifepristone with misoprostol 
group. 
Side-effects like nausea, pain, vomiting , fever were reported more 
in misoprostol group. 
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Mifepristone + misoprostol combination resulted in shorter 
induction- abortion interval and need for repeated doses of misoprostol  
was  reduced. 
Vaginal misoprostol is found to be economical than mifepristone. 
Hence mifepristone+ misoprostol combination was found to be 
more effective than misoprostol used alone in second trimester  
termination of pregnancy. 
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1 PRABHA 19	YR 11445 PRIMI 16	WKS UN	WED MISO	ONLY 1 3 2000	m	g 11hrs complete fever2 SUGANYA 20	YR 9837 PRIMI 16	WKS UN	WED MISO	ONLY 1 4 2400	m	g 14	hrs complete3 MOHANA 20	YR 8596 PRIMI 18	WKS UN	WED MISO	ONLY 1 3 2000	m	g 14	hrs complete Rigor,	vomiting4 KOKILA 20	YR 8348 PRIMI 20	WKS UN	WED MISO	ONLY 1 4 2400	m	g 14.3	hrs complete5 DHANABAKIYAM 20	YR 448 PRIMI 20	WKS UN	WED MISO	ONLY 1 3 2000	m	g 13	hrs complete6 MARIYAMMAL 19	YR 5062 PRIMI 16	WKS UN	WED MIFE	+	MISO 1 3 2000	m	g 12hrs complete7 SUMITHRA 20	YR 7448 PRIMI 16	WKS UN	WED MIFE	+	MISO 1 3 2000	m	g	 12hrs complete Rigor,	fever8 ANGAMMAL 20	YR 1959 PRIMI 16	WKS UN	WED MIFE	+	MISO 1 4 2400	m		g 16	hrs In	complete IE Rigor,	fever,	vomiting9 VANI 19	YR 2949 PRIMI 16	WKS UN	WED MIFE	+	MISO 1 4 2400	m	g 16.5	hrs In	complete IE pain10 KALIAMMAL 20	YR 2062 PRIMI 16	WKS UN	WED MIFE	+	MISO 1 4 2400	m	g 17	hrs In	complete IE Bleeding11 JAYAMALINI 21	YR 7773 PRIMI 20	WKS UN	WED MISO	ONLY 1 4 2400	m	g 14.5	hrs complete Rigor,	vomiting12 AMALA 23	YR 6633 PRIMI 20	WKS UN	WED MISO	ONLY 1 4 2400	m	g 16	hrs In	complete IE rigor,	vomiting,	diarrhoea13 KEERTHIKA 23	YR 6773 PRIMI 20	WKS UN	WED MISO	ONLY 1 4 2400	m	g 14.2	hrs complete nausea,	pain14 DILSATH	NISHA 21	YR 7383 PRIMI 20	WKS UN	WED MISO	ONLY 1 4 2400	m	g 14.4	hrs complete pain15 MANJU 22	YR 7400 PRIMI 18	WKS UN	WED MISO	ONLY 1 3 2000	m	g 14	hrs complete rigor,	fever16 SHENBAGAM 24	YR 7468 PRIMI 18	WKS UN	WED MISO	ONLY 1 3 2000	m	g 14.5	hrs complete rigor,	fever17 THILAGA 20	YR 7725 PRIMI 20	WKS UN	WED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete18 SUGANYA 19	YR 8216 PRIMI 20	WKS UN	WED MIFE	+	MISO 1 2 1600	m	g 10	hrs complete19 RAJESWARI 22	YR 8410 PRIMI 18	WKS UN	WED MIFE	+	MISO 1 3 2000	m	g 13	hrs complete nausea,	vomiting,	pain20 UMA 23	YR 6311 PRIMI 20	WKS ANOMALOUS MIFE	+	MISO 1 1 1200	m	g 6.5	hrs complete21 SALMA 20	YR 2329 PRIMI 20	WKS UN	WED MIFE	+	MISO 1 3 2000	m	g 12	hrs complete22 BANUMATHI 25	YR 6704 PRIMI 20	WKS ANOMALOUS MIFE	+	MISO 1 2 1600	m	g 11	hrs complete23 ERONICA 24	YR 6776 PRIMI 18	WKS ANOMALOUS MIFE	+	MISO 1 2 1600	m	g 10	hrs complete24 MARIYA	VERINIYA 22	YR 1531 PRIMI 18	WKS ANOMALOUS MIFE	+	MISO 1 4 2400	m	g 16	hrs In	complete IE nausea,diarrhoea,	vomiting25 SANGEETHA 22	YR 6029 PRIMI 18	WKS ANOMALOUS MISO	ONLY 1 4 2400	m	g 17	hrs In	complete IE pain C	u	-	T26 ANUSHA 24	YR 9916 G2	A1 18	WKS ANOMALOUS MISO	ONLY 1 4 2000	mg 14.5	hrs complete pain,	 C	u	-	T27 SATHYA 25	YR 11485 G2	P1	L120	WKS ANOMALOUS MISO	ONLY 1 1 2400	m	g 17.5	hrs In	complete IE rigor,	vomiting,	diarrhoea
MASTER CHART
S	
N
O
N
AM
E
AG
E
I.P
.N
O
PA
RI
TY
GA IN
D
IC
AT
IO
N
M
ET
H
O
D
IN
IT
IA
L	
D
O
SA
GE
	-	
80
0	
m
cg
RE
PE
AT
	D
O
SA
GE
	4
00
	m
cg
TO
TA
L	
D
O
SA
GE
IN
D
U
CT
IO
N
	
-	A
BO
RT
IO
N
	IN
TE
RV
AL
	IN
	H
RS
	
RE
SU
LT
	
AD
D
L	
.	
IN
TE
RV
EN
TI
O
N
SI
D
E	
-	E
FF
EC
TS
AD
D
L	
PR
O
CE
D
U
RE
28 SUMALATHA 23	YR 17668 G2	P1	L120	WKS ANOMALOUS MISO	ONLY 1 2 1600	m	g 10	hrs complete nausea,	pain29 ANJALAI 24	YR 13566 G2	P1	L117	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g 13	hrs complete rigor,	fever30 KALAISELVI 22	YR 5154 G2	P1	L118	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 16.5	hrs In	complete IE Vomiting,	Bleeding31 RIYANA	BANU 25	YR 2917 G2	P1	L118	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 15	hrs In	complete IE fever,	vomiting32 SUGUNA 22	YR 18125 G2	P1	L117	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13	hrs complete C	u	-	T33 SUGANTHI 23	YR 18446 G2	P1	L117	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 16.3	hrs In	complete IE nausea,	vomiting	,	pain34 JAYALAKSHMI 24	YR 14206 G2	P1	L118	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13	hrs complete vomiting,	diarrhoea35 INDRA 25	YR 14346 G2	P1	L118	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 14	hrs complete rigor,	vomiting36 SUBALAKSHMI 22	YR 6931 G2	P1	L118	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 10	hrs complete nausea C	u	-	T37 KAVITHA 21	YR 4484 G2	P1	L117	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 13	hrs incomplete IE rigor,	fever38 PREMA 23	YR 11445 PRIMI 20	WKS ANOMALOUS MIFE	+	MISO 1 3 2000	m	g	 13	hrs complete nausea,	vomiting	,	diarrhoea39 DURGA	DEVI 24	YR 8926 G2	P1	L117	WKS ANOMALOUS MIFE	+	MISO 1 3 2000	m	g	 12.5	hrs complete rigor,	fever40 BHAVANI 25	YR 6100 G2	P1	L118	WKS ANOMALOUS MIFE	+	MISO 1 2 1600	m	g 10	hrs complete C	u	-	T41 RANI 24	YR 206 G2	P1	L118	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 5	hrs complete C	u	-	T42 MEGALA 25	YR 439 G2	P1	L118	WKS UN	WANTED MIFE	+	MISO 1 2 1600	m	g 10	hrs complete C	u	-	T43 KRISHNAVENI 21	YR 1690 G2	P1	L117	WKS UN	WANTED MIFE	+	MISO 1 2 1600	m	g 9.2	hrs complete C	u	-	T44 SANDHIYA 23	YR 10542 G2	P1	L118	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete ` C	u	-	T45 ANUSIYA 24	YR 5616 G2	P1	L118	WKS UN	WANTED MIFE	+	MISO 1 3 2000	m	g	 11	hrs complete C	u	-	T
46 LAVANYA 25	YR 8342 G2	P1	L118	WKS CONTRACEPTIVE	FAILURE MIFE	+	MISO 1 2 1600	m	g 10	hrs complete C	u	-	T47 DEEPA 25	YR 3561 G2	P1	L118	WKS CONTRACEPTIVE	FAILURE MISO	ONLY 1 3 2000	m	g	 11	hrs complete nausea C	u	-	T48 SENJIAMMA 23	YR 4949 G2	P1	L117	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13	hrs complete rigor,	fever49 SUNDARI 24	YR 14059 G2	P1	L118	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13.2	hrs complete pain50 CHENNAMMAL 24	YR 7303 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 17	hrs incomplete IE51 YASMIN 28	YR 1980 G3	P2	L218	WKS CONTRACEPTIVE	FAILURE MISO	ONLY 1 4 2400	m	g 16.2	hrs In	complete IE nausea,	vomiting52 RENU 30	YR 8655 G3	P2	L217	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 9.2	hrs complete pain T	A	T53 SELVI 29	YR 7950 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 14.5	hrs complete rigor,	fever
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54 REETA 28	YR 4594 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 1 1200	m	g 8.2	hrs complete nausea T	AT55 VALLI 27	YR 14925 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13	hrs In	complete IE rigor,	fever56 SABRIN	BANU 28	YR 16636 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13	hrs complete nausea,	vomiting57 NADHIYA 27	YR 14705 G3	P2	L217	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 13	hrs complete58 CHITHRA 23	YR 11960 G2	P1	L117	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4	hrs complete C	u	-	T59 PRABHAVATHI 22	YR 12937 G2	P1	L117	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 9.5	hrs complete60 NITHYA 25	YR 13405 G2	P1	L118	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete C	u	-	T61 GANDHIMATHI 25	YR 14619 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4	hrs complete T	AT62 INDUMATHI 24	YR 16729 G3	P2	L217	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete T	A	T63 SIVASANKARI 22	YR 18387 G3	P2	L217	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete64 DURGA 28	YR 2460 G3	P2	L218		WKS UN	WANTED MIFE	+	MISO 1 2 1600	m	g 10	hrs complete65 PRIYANKA 29	YR 7797 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 5	hrs complete66 ELIZABETH 30	YR 10267 G3	P2	L217	WKS CONTRACEPTIVE	FAILURE MIFE	+	MISO 1 1 1200	m	g 7	hrs complete67 BHUVANESHVARI 27	YR 9065 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4.2	hrs complete T	AT68 AKILA 28	YR 13567 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 11	hrs complete rigor,	fever69 NAGAVALLI 26	YR 4461 G3	P2	L217	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 16	hrs In	complete IE pain70 SUDHA 27	YR 11015 G3	P2	L2 	17	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 10	hrs complete nausea,	pain71 REBEKA 26	YR 761 G3	P2	L218	WKS CONTRACEPTIVE	FAILURE MISO	ONLY 1 2 1600	m	g 11	hrs complete nausea,	pain72 NEELAVATHI 26	YR 11516 G3	P2	L218	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 11	hrs complete pain73 RAMYA 28	YR 14031 G3	P2	L220	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 19	hrs In	complete IE bleeding74 ROHINI 29	YR 15470 G3	P2	L220	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 10	hrs complete nausea,	pain75 RAJESHWARI 30	YR 8410 G3	P2	L219	WKS UN	WANTED MISO	ONLY 1 1 1200	m	g 7	hrs complete nausea,	pain76 SUBHA 26	YR 11015 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4.5	hrs complete77 NALINI 26	YR 11516 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7.2	hrs complete T	AT78 MANJULA 28	YR 2184 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete79 JOSPHINE 27	YR 10453 G3	P2	L217	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7.3	hrs complete nausea,	pain80 FARIDHA 28	YR 9853 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4.2	hrs complete T	A	T
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81 PADMA 30	YR 8607 G3	P2	L218	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4	hrs complete82 RAJAKUMARI 27	YR 11485 G3	P2	L220	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 5	hrs complete83 JAYA 28	YR 1747 G3	P2	L220	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7.4	hrs complete84 ARIFA 27	YR 16893 G3	P2	L220	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete85 GIRIJA 28	YR 17843 G3	P2	L219	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 5	hrs complete86 BANUPRIYA 26	YR 16769 G3	P2	L220	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete87 SUJATHA 39	YR 16015 G4	P3	L320	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 6.4	hrs complete T	A	T88 RENUKA 30	YR 16176 G4	P2	L220	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4	hrs complete T	A	T89 MALLIGA 36	YR 837 G5	P4	L419	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 4	hrs complete T	A	T90 HEMAVATHI 34	YR 15874 G4	P2	L2	A120	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 6.5	hrs complete nausea,	pain T	A	T91 SARASU 35	YR 16469 G4	P2	L2	A120	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 5	hrs complete T	A	T92 SUMATHI 27	YR 2245 G3	P2	L217	WKS UN	WANTED MIFE	+	MISO 1 1 1200	m	g 7	hrs complete nausea,	pain T	A	T93 MAHESWARI 33	YR 5754 G4	P2	L2	A118	WKS UN	WANTED MIFE	+	MISO 1 0 800	m	g 5	hrs complete T	A	T94 SURYA 29	YR 10356 G3	P2	L220	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 9	hrs complete T	A	T95 JAINBEE 28	YR 15478 G3	P2	L219	WKS UN	WANTED MISO	ONLY 1 1 1200	m	g 6.5	hrs complete T	A	T96 VANITHA 32	YR 17980 G4	P3	L320	WKS UN	WANTED MISO	ONLY 1 1 1200	m	g 7	hrs complete nausea,	fever T	A	T97 JOTHI 36	YR 1554 G4	P3	L320	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 16	hrs In	complete IE nausea,	pain T	A	T98 SOUNDARYA 33	YR 3693 G4	P3	L320	WKS UN	WANTED MISO	ONLY 1 2 1600	m	g 9	hrs complete pain T	A	T99 RIBILA 29	YR 12712 G3	P2	L219	WKS UN	WANTED MISO	ONLY 1 4 2400	m	g 18	hrs In	complete IE bleeding T	A	T100 AMULU 26	YR 18002 G3	P2	L220	WKS UN	WANTED MISO	ONLY 1 3 2000	m	g	 11.5	hrs complete nausea,	pain T	A	T
	 GA	-		GESTATIONAL		AGEIE	-	INSTRUNENTAL EVACUATION	TAT	-	TRANSABDOMINAL	TUBECTOMY
ABBREVIATIONS 
GA Gestational age 
HRS Hours 
I-A Int Induction Abortion Interval 
mcg Microgram 
mg milligram 
MTP Medical Termination of Pregnancy 
Mife+Miso - mifepristone+misoprostol 
Miso Misoprostol 
NS Not Significant 
PG Prostaglandin 
S Significant 
SD Standard Deviation 
WK Week 
 
